Navigation Links
Advanced Life Sciences Sees Funding Opportunity for Restanza in New HHS Medical Countermeasure Report
Date:8/24/2010

and other high priority biodefense pathogens, including plague and tularemia. The FDA has designated Restanza as an orphan drug for the prophylactic treatment of inhalation anthrax post exposure, as well as for use in treating plague and tularemia, but the drug is not yet approved for these or any other indications.

Advanced Life Science recently announced that it has reached agreement with the United States Food and Drug Administration (FDA), under the Special Protocol Assessment (SPA) process, on the design of its planned Phase 3 study of Restanza to treat CABP.

About Advanced Life Sciences

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and respiratory diseases. The Company's lead candidate, Restanza, is a novel once-a-day oral antibiotic in late-stage development for the treatment of respiratory tract infections including CABP and biodefense pathogens including anthrax, plague and tularemia. For more information, please visit us on the web at www.advancedlifesciences.com or follow us on twitter at http://twitter.com/advancedlifesci.

Forward-Looking Statements

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements represent our management's judgment regarding future events.  The Company does not undertake any obligations to update any forward-looking statements whether as a result of new information, future events or otherwise.  Our actual results could differ materially from those discussed herein due to several factors including the success and timing of our clinical trials and our ability to obtain
'/>"/>

SOURCE Advanced Life Sciences Holdings, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Baxter Awarded Pandemic Advanced Supply Contract from the Department of Health
3. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
4. Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma
5. Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents
6. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
7. Advanced Life Sciences to Present Data on Selected Cethromycin Therapeutic Studies at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
8. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
9. Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
10. Avastin Achieves Impressive Rate of Curative Surgery in Patients with Advanced Colorectal Cancer
11. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015  Mallinckrodt plc (NYSE: ... Directors has approved a share repurchase program. The open-ended ... million of Mallinckrodt plc ordinary shares. ... remain top priorities as we continue to pursue a ...
(Date:1/22/2015)... privately held medical device company, announced today that it ... Corporation (Tokyo Stock Exchange TYO: 8001) to sell its ... in Japan . ViewRay,s technology, the ... MRI-guided radiation therapy system that images and treats cancer ...
(Date:1/22/2015)... Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty ... disease and overall health is pleased to provide you with ... outlook for 2015 from the CEO, Mr. Eugene Bortoluzzi ... like to take this opportunity to share with you the ...
Breaking Medicine Technology:Mallinckrodt plc Announces Share Repurchase Program 2Mallinckrodt plc Announces Share Repurchase Program 3Mallinckrodt plc Announces Share Repurchase Program 4ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2Pivotal Therapeutics: Year in Review and CEO Update 2Pivotal Therapeutics: Year in Review and CEO Update 3Pivotal Therapeutics: Year in Review and CEO Update 4Pivotal Therapeutics: Year in Review and CEO Update 5Pivotal Therapeutics: Year in Review and CEO Update 6Pivotal Therapeutics: Year in Review and CEO Update 7
... 2012  BioParadox, Inc., a regenerative medicine company pioneering ... a strategic alliance with Fogarty Institute for Innovation.  ... working with the Fogarty Institute for Innovation known ... patients with challenging problems.  The Fogarty Institute,s unique ...
... 2, 2012 Synthetic Genomics, Inc. (SGI), a ... to solve a variety of global needs, and ... in production and supply of oligonucleotides, today jointly ... to manufacture, market, and commercialize small synthetic gene ...
Cached Medicine Technology:BioParadox Announces Partnership with Fogarty Institute for Innovation 2Synthetic Genomics, Inc. and Integrated DNA Technologies, Inc. Sign Agreement to Manufacture, Market, and Commercialize Small Synthetic Gene Products Using SGI Technology 2
(Date:1/22/2015)... 2015 The Incredible Bulk is a revolutionary ... increase lean muscle by up to 30lbs in less than ... of HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. , “Our ... step-by-step, scientific diet formula that allows the body to pack ...
(Date:1/22/2015)... The federal court overseeing thousands of vaginal ... Southern District of West Virginia has upheld a $2 million ... bellwether trial. In an Order dated January 21st, the Court ... that C.R. Bard had not proven a miscarriage of justice. ...
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post ... insurance policy . , Auto insurance quotes help many ... no longer necessary to call an agent or visit an ... on a single website: http://autocarinsurancebest.com/ . , Every business ...
(Date:1/22/2015)... A study recently published in ... Medicine & Science in Sports & Exercise shows ... reduce gastrointestinal (GI) problems associated with physical strain ... the double-blind, placebo-controlled study took 10 grams of ...
(Date:1/22/2015)... Four years since the release of their debut recording Love is ... Avasa & Matthew Love – the duo are pleased to announce ... White Swan Records on February 24, 2015. , THE ROAD offers ... to all of us to walk out of the mire of ...
Breaking Medicine News(10 mins):Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:Commercial Auto Insurance Provides Several Important Features! 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4
... in statewide election while caregivers file over 125,000 protests , ... In a statewide vote of healthcare workers conducted by ... counted but the result is clear: healthcare workers overwhelmingly oppose ... and healthcare advocates are joining them in protest. , ...
... Millions View an Accurate and Uplifting TV Movie Portrayal of ... N.Y., Dec. 11 Nearly 12 million people watched last ... the Class," a made-for-TV movie based on the true story ... Syndrome (TS) to become an award winning teacher. The ...
... Prescription products, used to prep for colonoscopy, may harm ... warnings , , THURSDAY, Dec. 11 (HealthDay News) -- Two ... colonoscopy may cause kidney damage, the U.S. Food and ... would now require a black-box warning on the oral ...
... from one of the largest studies in hormone receptor ... , PHILADELPHIA, Dec. 11 ... TYKERB(R) (lapatinib) plus Femara(R) (letrozole) versus letrozole alone ... (HR+) metastatic breast cancer. In the study, women diagnosed ...
... for,Medical Research (AFMR) announces its full support of Former ... Health and Human Services,secretary. Mr. Daschle will serve as ... care system. , ... AFMR believes firmly that,improving clinical research in the U.S., ...
... by Matthew L. Myers, President, Campaign for Tobacco-Free Kids: , ... , , It is good ... Future survey released today finds that smoking rates among 8th, ... recorded in this survey for all three grades. However, ...
Cached Medicine News:Health News:Boycott Prevails in Sham SEIU Vote; Lawmakers and Advocates Join Healthcare Workers in Opposing Forced Union Merger 2Health News:Hallmark Hall of Fame Collaboration with Patient Organization Equals Extraordinary Success 2Health News:FDA Puts Black-Box Warning on Bowel-Cleansing Drugs 2Health News:FDA Puts Black-Box Warning on Bowel-Cleansing Drugs 3Health News:Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer 2Health News:Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer 3Health News:Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer 4Health News:Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer 5Health News:Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer 6Health News:Combination of TYKERB(R) (lapatinib) Plus Letrozole Demonstrated Significant Improvement in Delaying Disease Progression for HER2+/ErbB2+ Post-Menopausal Metastatic Breast Cancer 7Health News:The American Federation for Medical Research Says Daschle Must Cure Clinical Research Crisis if Change Is To Take Hold in U.S. Health Care System 2Health News:The American Federation for Medical Research Says Daschle Must Cure Clinical Research Crisis if Change Is To Take Hold in U.S. Health Care System 3Health News:The American Federation for Medical Research Says Daschle Must Cure Clinical Research Crisis if Change Is To Take Hold in U.S. Health Care System 4Health News:New Survey Shows Continued Progress in Reducing Youth Smoking; Congress, States Can Accelerate Declines by Implementing Proven Solutions 2Health News:New Survey Shows Continued Progress in Reducing Youth Smoking; Congress, States Can Accelerate Declines by Implementing Proven Solutions 3Health News:New Survey Shows Continued Progress in Reducing Youth Smoking; Congress, States Can Accelerate Declines by Implementing Proven Solutions 4
For the quantitative in vitro determination of Triglycerides in serum and plasma....
The CK method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of creatine kinase activity in serum and plasma...
For the quantitative in vitro determination of Cholesterol in serum and plasma....
For the quantitative in vitro determination of Alanine Aminotransferase (ALT) in serum and plasma....
Medicine Products: